4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
About Eisai Inc.
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
For more information about Eisai, please visit www.eisai.com
303 articles with Eisai Inc.
BioArctic AB announced that the company's partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 at the 13th Clinical Trials on Alzheimer's Disease Conference on November 4-7.
Eisai Continues MOMENTUM 2 Expanded Access Program (Study 405) for Patients Previously Prescribed Lorcaserin to Treat Dravet and Other Refractory Epilepsies [30-September-2020] WOODCLIFF LAKE, N.J. , Sept. 30, 2020 /PRNewswire/ -- Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 cli
9/28/2020The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam). Eisai Vietnam is a wholly-owned subsidiary of Eisai.
Eisai to Present New Data Highlighting KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and Eribulin Platform at ESMO 2020
Eisai will present two late breakers and 10 e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020.
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference
Nine presentations, including a long-term efficacy and safety analysis of DAYVIGO in adults ages 65 and older and interim results from a pilot study on the transition from zolpidem to DAYVIGO, to be shared at the meeting
Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AAIC 2020, Including BAN2401 and Lemborexant Data and a Biomarker Symposium
- One oral presentation and eight posters, highlighting Eisai's investigational novel therapies being studied to treat Alzheimer's disease (AD) and its clinical symptoms - New biomarker research approaches will be shared as part of symposium featuring prominent experts in the field
BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020
BioArctic AB announced that the company's partner Eisai will present the study design of the Phase 3 program AHEAD 3-45 at the Alzheimer's Association International Conference 2020 on July 27-31. In the study, the therapeutic effect of drug candidate BAN2401 on the progression of preclinical, asymptomatic, Alzheimer's disease will be investigated.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck and Eisai over their Lenvima and Keytruda combination for first-line treatment of unresectable hepatocellular carcinoma (HCC).
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Merck, known as MSD outside the United States and Canada, and Eisai announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding Merck’s and Eisai’s applications seeking accelerated approval of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO® (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab
Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin mesylate)
Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology's ASCO20 Virtual Scientific Program from May 29-31.
Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Eisai announced today that positive results from a Phase 2 study (Study 111/KEYNOTE-146) of lenvatinib (marketed as LENVIMA ® ), an orally available kinase inhibitor discovered by Eisai, in combination with pembrolizumab (marketed as KEYTRUDA ® ), Merck's anti-PD-1 therapy, in patients with advanced endometrial carcinoma hav
Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Eisai presented results from a Phase 2 trial assessing the efficacy and safety of lenvatinib in combination with everolimus in patients with unresectable advanced or metastatic non-clear cell renal cell carcinoma at the 2020 Genitourinary Cancers Symposium in San Francisco from February 13-15.
Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S.